论文部分内容阅读
(续中国药理学通报,1993;9(3);240)2.25 前列腺素受体名称DP EP_1,EP_2,EP_3 FP IP TP曾用名称前列腺素D前列素E前列腺F前列腺素I_z血栓烷强度顺序”D>E、F、I、T E>F、I>D、T F>D>E>I、TI>D、E、F>T T=H》D、E、F、I选择性激动剂BW245C EP_3:MB28767 前列氟醇U46619ZK110841 STA_ZI—BOP选择性拮抗剂BWA868C(9.3)EP_1:SC19220(5.6)——GR32191(8.8)AH6809(6.8)SQ29548(8.7)放射性配基[~3H]PGD_2[~3H]PGE_2 [~3H]PGF_(2a)[~3h][~3H]SQ29548(4.5 nmol.L~(-1))[~1251]SAP
(Continued from Chinese Pharmacological Bulletin, 1993; 9 (3); 240) 2.25 Prostaglandin Receptor Names DP EP_1, EP_2, EP_3 FP IP TP Previous Name Prostaglandin D Prostaglandin E Prostate F Prostaglandin I_z Thromboxane Intensity Sequence “ TI> D, E, F> TT = H ”D, E, F, I selective agonist BW245C EP_3: MB28767 Sevoflurane U46619ZK110841 STA_ZI-BOP Selective antagonist BWA868C (9.3) EP1: SC19220 (5.6) - GR32191 (8.8) AH6809 (6.8) SQ29548 ~ 3H] PGF_ (2a) [~ 3h] [~ 3H] SQ29548 (4.5 nmol.L -1) [~ 1251] SAP